Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Vertex Pharmaceuticals' largest ...

GameSpot may get a commission from retail offers. Over a decade after a disastrous debut plagued with faceless NPCs and frame rate issues, Assassin's Creed Unity is rounding out its comeback story ...

TL;DR: Unity's upgraded AI, launching in beta at GDC, enables developers to create full casual games using natural language prompts without coding. Leveraging advanced models from OpenAI and Meta, ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...

Unity Software (U) plunged 25% on Wednesday after the gaming development platform reported its fourth quarter 2025 financial results and outlook. Although the fourth quarter results topped estimates, ...

Unity reports fourth-quarter results that "comfortably exceeded" its high-end guidance, including a boost in its Create Solutions and Grow Solutions revenue by 8% and 11%, respectively. Overall ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...